Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 448 (CSE: $TER.C) (CSE: $CURA.C) (OTC: $HEMP)
Delta, Kelowna, BC, July 31, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,
www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/073120-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07311TER-CURA-HEMP.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Open Book Extracts announced its expansion of operations and distribution channels into Asia, Israel and most recently, South Africa.
To serve a recently estimated $6.4 billion market opportunity for cannabis in South Africa, OBX was named a principal distribution partner of Peter Bodill Agencies LTD of South Africa. With more than 30 years in the agency/distribution business in South Africa, Peter Bodill Agencies represents manufacturers that specialize in supplying some of the world’s finest products, such as vitamin mixes, probiotics and industrial ingredients throughout the entire country. OBX joins global commercial distribution partner, Prinova Nagase Group, in a short list of principals vetted and approved by Peter Bodill Agencies for South African distribution.
“Quality, safety and reliability are essential in the burgeoning South Africa cannabis market,” stated Peter Bodill, director of Peter Bodill Agencies LTD. “The caliber of the team and products from Open Book Extracts has exceeded our expectations. We are excited to be able to provide its high-quality CBD products, innovative cannabinoid blends and pure rare cannabinoids to our clients.”
In addition to the South Africa distribution channel, OBX expanded its footprint into Asia, appointing Laurie Goldberg as OBX Asia’s chief executive officer. Goldberg, who founded and recently sold AmeriCraft Imports Limited, a Hong Kong-based craft beer importer and distributor, will lead expansion efforts into the Asia market.
“With the demand for CBD products in Asia growing rapidly, it is paramount for leading brands to have a reputable, quality supplier like Open Book Extracts,” stated Goldberg. “The fact that OBX is cGMP certified, able to deliver pharma-grade purity levels and is well versed in global market distribution ensures that we will meet the Asian market demand for high-quality, safe cannabinoid products.”
“We’re thrilled to expand our footprint to provide safe and efficacious cannabinoid products worldwide,” stated Dave Neundorfer, chief executive officer at OBX. “While we are glad to see countries roll out regulations to permit non-THC cannabinoids in food, beverages and personal care products, we’re also planning clinical trials for safety and efficacy to support dietary supplement and pharmaceutical registrations.”
The establishment of global distribution channels follows closely on the heels of Open Book Extracts’ recent acquisition of Chilmark Labs and its Israeli affiliate, Beetlebung Pharma Ltd., enabling the manufacturing of high-purity rare and minor cannabinoids at commercial scale, and further unlocking the therapeutic potential of cannabinoid-based products.
TerrAscend Corp. (CSE:TER) (OTCQX: TRSSF) today announced that it has officially opened its seventh retail dispensary location. The new 4,200 square foot Apothecarium dispensary, located at 2312 Telegraph Ave, Berkeley, CA is the company's fourth California dispensary, and TerrAscend's seventh dispensary nationwide.
The Apothecarium Berkeley is a full-service recreational and medical cannabis dispensary featuring a stylish, upscale design and a staff of highly trained cannabis consultants to assist guests. The store carries a wide variety of cannabis products, including edibles, flowers, vaping products, concentrates, capsules, tinctures, topicals, and ancillary products. The new location offers online ordering at apothecarium.com for pickup and delivery.
"We are excited to begin serving our East Bay customers from a beautiful new location on Telegraph Avenue," said Ryan Hudson, CEO, and co-founder of The Apothecarium. "At The Apothecarium, our focus is on education. We aim to provide one-on-one consultations that help our patients and customers find the right products for their needs. Whether they are looking for help in-person, by phone or via web chat, our cannabis consultants are here to help."
"For nearly a decade The Apothecarium has set the standard for dispensary design and customer service," said Jason Ackerman, CEO of TerrAscend. "The Apothecarium Berkeley is raising the bar again with a refined look and upgraded technology that brings the dispensary's famous consultations and cannabis education classes online. We're delighted to expand our footprint; Berkeley is our fourth California dispensary and our first in the East Bay."
The Apothecarium Berkeley is designed to be comfortable and easy to navigate for seniors, first-time dispensary visitors, and patients with serious medical conditions. The dispensary features The Apothecarium's typical mix of neo-Victorian furnishings, modern touches, and plenty of natural light. The store was designed by the same team behind The Apothecarium's three San Francisco dispensaries: architect Vincent Gonzaga and the interior design firm, Urban Chalet.
All Apothecarium dispensaries have implemented strict safety standards to protect guests and team members. Our California safety protocols include strict social distancing inside and outside the dispensaries, a mask requirement for everyone inside the dispensaries, no contact check-in procedures and ongoing sanitizing throughout the day.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) announced the launch of Curaleaf Sublingual Tablets in Florida. These cube-shaped, berry-flavored bites will provide the state's medical patients with a discreet, sugar-free yet fruity alternative form of medication.
Curaleaf's new Sublingual Tablets, which will be in 30-piece jars, contain 5mg of high-quality cannabis oil per piece, which allows patients to manage their treatment plan with confidence and ease. Each bite, which is made to be ingested orally or sublingually, is translucent in color and features a refreshing "Arctic Berry" flavor. The new product will be sold at all of the Company's 28 operating dispensaries in Florida with a phased roll-out between August 8th - August 20th. Limited quantities will be released to pre-existing loyalty patients beginning tomorrow, July 30th. For more information on the product roll-out cadence, please visit
https://curaleaf.com/blog/curaleaf-sublingual-tablets.
"The demand for alternative cannabis form functions in Florida has been mounting for years, and we are thrilled to offer our patients an exciting new product -- Sublingual Tablets," said Joe Lusardi, Chief Executive Officer at Curaleaf. "Our success is driven by listening to and meeting the needs of our patients, and we're incredibly proud to be first to market in Florida with this new option in cannabis medicine. By providing high-quality products in a variety of administration routes, we are better positioned to improve our patients' lives, which has been our mission since day one."
Earlier this summer, Curaleaf began selling "Shorties," a pre-roll flower product, in response to the requests of their Florida patients. As an additional offering to the classic 1g pre-roll, patients can now enjoy freshly harvested flower by way of these conveniently sized .4g pre-rolls.
Florida's continued growth in patient registration makes it one of the nation's fastest-growing medical cannabis markets in the country. Currently, there are over 377,000 medical patients enrolled in the Florida program - about 1.7% of the state's population - with approximately 5,000 new patients enrolling each week. To ensure the best possible service to the increasing number of medical patients, Curaleaf is in the process of expanding its Florida presence, adding to current grow capacity and planning to open at least five new dispensaries by Q4.
During the COVID-19 pandemic, cannabis businesses have been deemed an essential service in most states, including Florida. Curaleaf remains committed to serving patients and customers with the products they rely on while implementing heightened safety and hygienic measures in all its facilities.
Curaleaf's dispensary regular operating hours remain in effect, and free statewide delivery is always available for Florida medical patients. Throughout the year, discounts are offered to senior citizens, military veterans, pediatric patients, and recipients of government financial assistance. Please visit www.curaleaf.com/locations to find a dispensary near you.
Geocann announced that the company has commercialized the first oral dose application that overcomes the well-known bioavailability challenges of science-backed, key ingredients found in popular immunity support products. The multi-patented VESIsorb® delivery system provides the much-needed solution that turns the following poorly absorbed individual compounds into a synergistic, 4-in-1 formulation with dramatic improvements in absorption and bioavailability:
● 50 mg curcumin from turmeric root;
● 15 mg cannabidiol (CBD) from broad spectrum hemp extract;
● 7 mg beta-caryophyllene (BCP) that has received FDA GRAS status; and
● 200 IU vitamin D3.
“These ingredients have been strategically selected for their immunity support and anti-inflammatory properties, but are notorious for showing limited bioavailability due to their lipophilicity and extensive first-pass metabolism,” said Anthony Petraglia, M.D., Chief Medical Officer. “With a successful track record over the past fifteen years, VESIsorb® has consistently demonstrated its ability to mitigate these negative effects while significantly improving the pharmacokinetic performance of natural ingredients. To put it simply, bioavailability is the key to providing an immunity support product that delivers its desired health benefits.”
This formulation milestone comes on the heels of a study that was published in the peer-reviewed journal, Molecules, showcasing the numerous advantages of broad spectrum hemp extract formulated with VESIsorb® to that of the same broad spectrum hemp extract combined with medium chain triglycerides (MCT) oil. Key findings included that an important subgroup showed statistically significant improvements for all measured pharmacokinetic parameters, including a 712% increase in maximal plasma CBD concentration (Cmax), a 449% improvement in total CBD exposure over time [area under the curve (AUC)], and a 400% improvement in time to peak absorption (Tmax).
“Geocann has a strategic focus to deliver cannabinoid and terpene products with an unmatched body of supporting scientific evidence that address the most pressing health concerns,” said Sam Davidson, Chief Operating Officer. “The marketplace demand for natural immunity support products is unprecedented, and the relationship between a healthy immune system and a strong endocannabinoid system (ECS) is well-documented. More than ever, we are committed to pioneering these innovative solutions with our technical formulation expertise, rigorous product development protocol, and global distribution infrastructure.”
Geocann has the exclusive global rights to the patented VESIsorb® drug delivery technology for cannabinoids, terpenes, and flavonoid formulations. The company is strategically partnering with leading lifestyle brands that share a commitment to superior product safety, quality, and performance. The VESIsorb® drug delivery system has been successfully applied to a wide range of cannabis based product applications, including soft gel and hard shell capsules, functional foods (e.g. gummies) and beverages, powder systems, tinctures, sublingual sprays, and topically applied formulations.
Hemp, Inc. (OTC: HEMP) commended Congress for approving an amendment to the National Defense Authorization Act (NDAA) permitting military service members to use CBD and hemp-derived products.
The amendment supersedes months of confusion surrounding cannabidiol (CBD) policy earlier this year and addresses policies across military organizations following the legalization of hemp in the 2018 Farm Bill. The amendment also includes a measure allowing heads of military branches to issue reenlistment waivers to members of the armed forces who admit to using cannabis.
The approved measure is also celebrated by Hemp Inc.’s strategic hemp growing partner Veterans Village Kins Community in Arizona which is designed to grow hemp for CBD products that benefit veterans, generate revenues for the residents, and to support the holistic healing and learning center at the heart of the community.
“This is a step in the right direction for cannabis policy reform provisions and we’re very pleased that Congress has taken the initiative to allow military members to utilize the natural benefits of hemp to remedy the mental and physical effects of serving our country,” said Hemp, Inc. CEO Bruce Perlowin. “Working with our veteran partners at Veteran Village Kins Community in Arizona, Inc. we can see the good that CBD has on former military service members and this only illustrates the therapeutic and preventative effects it can have on active members as well.”
According to the Department of Defense Suicide Prevention (DoDSER) 2017 annual report, there were 1,397 non-fatal suicide attempts by active-duty service members. However, a 2015 study titled ‘Cannabidiol as a Potential Treatment for Anxiety Disorders’ showed CBD usage to be most effective in helping people deal with traumatic events within an hour of the experience, suggesting that using CBD while on active duty could probably decrease the development of PTSD and severe anxiety before it is too late.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
